Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5547782 | 0.98 | TSHR (0.40) | TSHRALDH1A1DNM1TDP1LTA4H | |
| SCHEMBL28915967 | 0.89 | DNM1 (0.42) | TSHRDNM1TDP1LTA4HL3MBTL1 | |
| SCHEMBL8894973 | 0.89 | DNM1 (0.42) | TSHRDNM1TDP1LTA4HL3MBTL1 | |
| SCHEMBL26160891 | 0.87 | DNM1 (0.41) | TSHRDNM1TDP1LTA4HL3MBTL1 | |
| SCHEMBL10444399 | 0.87 | DNM1 (0.39) | TSHRDNM1TDP1LTA4HL3MBTL1 | |
| SCHEMBL4722516 | 0.80 | L3MBTL1 (0.34) | TDP1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL4723247 | 0.78 | L3MBTL1 (0.36) | TSHRTDP1L3MBTL1SIGMAR1MEN1 | |
| SCHEMBL4724012 | 0.77 | SIGMAR1 (0.35) | TDP1L3MBTL1SIGMAR1MEN1KMT2A | |
| SCHEMBL8607396 | 0.76 | SIGMAR1 (0.33) | L3MBTL1SIGMAR1 | |
| SCHEMBL4722021 | 0.75 | L3MBTL1 (0.34) | TDP1L3MBTL1SIGMAR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | HOLMES-FARLEY STEPHEN R | 2007-08-16 | — | — | US | disclosed |
| US-7125547-B2 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION (US) | 2006-10-24 | — | — | US | disclosed |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | GENZYME CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6610283-B1 | Method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a | GENZYME CORPORATION | 2003-08-26 | — | — | US | disclosed |
| EP-1094801-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 2001-05-02 | — | — | EP | disclosed |
| US-6203785-B1 | ADMINISTERING CROSSLINKED CATIONIC POLYMER ANTICHOLESTEROL AGENTS | GELTEX PHARMACEUTICALS, INC. | 2001-03-20 | — | — | US | disclosed |
| WO-1999022743-A1 | POLY(DIALLYLAMINE)-BASED PHOSPHATE BINDERS | GELTEX PHARMACEUTICALS, INC. (US) | 1999-05-14 | — | — | WO | disclosed |
| WO-1998029107-A2 | POLY(DIALLYLAMINE)-BASED BILE ACID SEQUESTRANTS | GELTEX PHARMACEUTICALS, INC. (US) | 1998-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070190021-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | SIGMAR1 1392/4885TSHR 4075/4885ALDH1A1 2873/4885 |
| US-20040151687-A1 | Poly(diallylamine)-based bile acid sequestrants | NR1H4, SLC10A2, SLC10A1 | SIGMAR1 1335/4885TSHR 4388/4885ALDH1A1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.